Zhong Lun Law Firm Supplementary Legal Opinion II on Qianli Beiyikang Beijing Stock Exchange IPO

Sichuan Qianli Beiyikang Medical Technology Co., Ltd. is a high-tech enterprise specializing in the R&D, production and sales of medical devices. The company's main products include medical dressings, medical adhesives, medical sutures, etc. The company has passed ISO13485 quality management system certification and EU CE certification.


Zhong Lun Law Firm Supplementary Legal Opinion II on Qianli Beiyikang Beijing Stock Exchange IPO - cover page
Brand
中伦律师事务所
Document type
Other
Language
Chinese
Pages
88
File format
PDF
File size
965 KB
Published
25 November, 2023
Updated
25 November, 2023
MD5 checksum
B5CE5B9D592F348C4216B757F89331F8

About this manual

This is a supplemental legal opinion (II) issued in September 2022 by Beijing Zhong Lun Law Firm for Sichuan Qianli Beiyikang Medical Technology Co., Ltd. It supplements the earlier legal opinion, lawyer's work report and supplemental legal opinion (I) prepared for the company's public offering of shares to non-specific qualified investors and listing on the Beijing Stock Exchange, and covers changes in legal matters from January 1, 2022 to June 30, 2022, the supplementary reporting period.

The document updates matters related to the offering and listing, including approvals and authorizations, the issuer's subject qualification, the substantive conditions for the offering, the issuer's property, tax, labor and social security matters, use of raised funds and litigation, and updates responses to questions in the review inquiry letter. It also includes nine appendices covering new domestic and foreign patents, trademarks, branches, leased premises, ongoing litigation, inspection reports and product quality liability arrangements with major customers and suppliers. This manual is written in Chinese.

What's inside

  • Update on Matters Relating to the Offering and Listing
  • Approval and Authorization of the Offering and Listing
  • Subject Qualification of the Issuer
  • Substantive Conditions for the Offering and Listing
  • Independence of the Issuer
  • Related-Party Transactions and Horizontal Competition
  • Major Assets of the Issuer
  • Tax Matters of the Issuer
  • Use of Raised Funds
  • Update on Replies to Review Inquiry Letter Questions

Frequently asked questions

What is the adjusted issue price floor per share?

The board resolution of September 20, 2022 adjusted the issue price floor from 45 yuan per share to 31.8 yuan per share, with the other terms of the offering unchanged.

What period does this supplemental legal opinion cover?

It covers legal matters of the issuer from January 1, 2022 to June 30, 2022, the supplementary reporting period, following the audit extended to June 30, 2022.

Does the issuer still qualify as the subject of the offering and listing?

Yes; as of the date of this supplemental legal opinion the issuer remains a legally established and validly existing joint stock company and an innovation-tier listed company on the National Equities Exchange and Quotations for at least twelve consecutive months.

What approvals are still needed before the offering and listing?

The resolution adjusting the listing plan still needs approval by the issuer's shareholders' meeting, and the offering and listing still need to pass Beijing Stock Exchange review and obtain registration consent from the China Securities Regulatory Commission.

Download PDF (965 KB)